Abiopharma

FDA approve EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Regencell Bioscience Holdings Limited Announces the Forward Stock Split is Effected

GlycoMimetics Inc. (GLYC) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: GlycoMimetics, Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: GlycoMimetics, Inc. - Common Stock. New value: GlycoMimetics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: D. New value: GlycoMimetics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: -. New value: D.

NASDAQ symbol attribute type Test_mode was changed. Previous value: -. New value: N.

NASDAQ symbol attribute type Security_Name was changed. Previous value: -. New value: Crescent Biopharma, Inc. - Common Stock.

Shrinking Season 3: Everything We Know So Far

Regencell Bioscience Holdings Limited Announces the Forward Stock Split is Effected

FTRE Shareholders with Large Losses are Encouraged to Seek Counsel - Contact Robbins LLP for Information About Leading the Class Action Against Fortrea Holdings, Inc.

Prothena - Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinsons Disease

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinsons Disease

Cordlife Group Limited - Announcement